TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Amusement parks fight off home entertainment threat
  2. S&P 500 logs 47th record high close for year
  3. Caution creeps into economic picture as consumer, business spending taper
  4. State officials prompt UPMC, Highmark to go to mediation to resolve Medicare dispute
  5. Westinghouse to construct colossal nuke plant in Turkey
  6. Federal agency checking whether Highmark has enough doctors in Medicare plan
  7. Retailers that won’t open on Thanksgiving hope move pays off
  8. BNY Mellon trader fired in conduct probe
  9. Butler County firm Deep Well Services tackles tough gas wells
  10. Lower gasoline prices fail to spur consumer spending
  11. 5 strategies to tackle student loan debt
Subscribe today! Click here for our subscription offers.